Amedisys, Inc.
Amedisys, Inc. AMED Peers
See (AMED) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AMED | $94.47 | -0.03% | 3.10B | 34.86 | $2.71 | N/A |
| HCA | $367.59 | -0.14% | 88.43B | 16.32 | $22.53 | +0.74% |
| FMS | $27.83 | -0.61% | 16.33B | 23.39 | $1.19 | +2.28% |
| THC | $159.63 | +1.22% | 14.83B | 10.23 | $15.60 | N/A |
| SOLV | $71.12 | -3.26% | 12.30B | 32.77 | $2.17 | N/A |
| UHS | $187.90 | -2.22% | 12.11B | 10.56 | $17.79 | +0.42% |
| EHC | $119.25 | +1.39% | 12.02B | 24.54 | $4.86 | +0.55% |
| DVA | $139.84 | -2.88% | 10.56B | 13.87 | $10.08 | N/A |
| OSH | $39.00 | +0.08% | 9.52B | -17.65 | -$2.21 | N/A |
| ENSG | $144.79 | +0.86% | 8.32B | 27.37 | $5.29 | +0.17% |
Stock Comparison
AMED vs HCA Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, HCA has a market cap of 88.43B. Regarding current trading prices, AMED is priced at $94.47, while HCA trades at $367.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas HCA's P/E ratio is 16.32. In terms of profitability, AMED's ROE is +0.10%, compared to HCA's ROE of -2.36%. Regarding short-term risk, AMED is less volatile compared to HCA. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs FMS Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, FMS has a market cap of 16.33B. Regarding current trading prices, AMED is priced at $94.47, while FMS trades at $27.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas FMS's P/E ratio is 23.39. In terms of profitability, AMED's ROE is +0.10%, compared to FMS's ROE of +0.04%. Regarding short-term risk, AMED is less volatile compared to FMS. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs THC Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, THC has a market cap of 14.83B. Regarding current trading prices, AMED is priced at $94.47, while THC trades at $159.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas THC's P/E ratio is 10.23. In terms of profitability, AMED's ROE is +0.10%, compared to THC's ROE of +0.37%. Regarding short-term risk, AMED is less volatile compared to THC. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs SOLV Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, SOLV has a market cap of 12.30B. Regarding current trading prices, AMED is priced at $94.47, while SOLV trades at $71.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas SOLV's P/E ratio is 32.77. In terms of profitability, AMED's ROE is +0.10%, compared to SOLV's ROE of +0.12%. Regarding short-term risk, AMED is less volatile compared to SOLV. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs UHS Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, UHS has a market cap of 12.11B. Regarding current trading prices, AMED is priced at $94.47, while UHS trades at $187.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas UHS's P/E ratio is 10.56. In terms of profitability, AMED's ROE is +0.10%, compared to UHS's ROE of +0.18%. Regarding short-term risk, AMED is less volatile compared to UHS. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs EHC Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, EHC has a market cap of 12.02B. Regarding current trading prices, AMED is priced at $94.47, while EHC trades at $119.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas EHC's P/E ratio is 24.54. In terms of profitability, AMED's ROE is +0.10%, compared to EHC's ROE of +0.25%. Regarding short-term risk, AMED is less volatile compared to EHC. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs DVA Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, DVA has a market cap of 10.56B. Regarding current trading prices, AMED is priced at $94.47, while DVA trades at $139.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas DVA's P/E ratio is 13.87. In terms of profitability, AMED's ROE is +0.10%, compared to DVA's ROE of +3.94%. Regarding short-term risk, AMED is less volatile compared to DVA. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs OSH Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, OSH has a market cap of 9.52B. Regarding current trading prices, AMED is priced at $94.47, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas OSH's P/E ratio is -17.65. In terms of profitability, AMED's ROE is +0.10%, compared to OSH's ROE of +4.64%. Regarding short-term risk, AMED is more volatile compared to OSH. This indicates potentially higher risk in terms of short-term price fluctuations for AMED.
AMED vs ENSG Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, ENSG has a market cap of 8.32B. Regarding current trading prices, AMED is priced at $94.47, while ENSG trades at $144.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas ENSG's P/E ratio is 27.37. In terms of profitability, AMED's ROE is +0.10%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, AMED is less volatile compared to ENSG. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs CHE Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, CHE has a market cap of 8.10B. Regarding current trading prices, AMED is priced at $94.47, while CHE trades at $553.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas CHE's P/E ratio is 27.01. In terms of profitability, AMED's ROE is +0.10%, compared to CHE's ROE of +0.26%. Regarding short-term risk, AMED is less volatile compared to CHE. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs LHCG Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, LHCG has a market cap of 5.29B. Regarding current trading prices, AMED is priced at $94.47, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas LHCG's P/E ratio is 82.83. In terms of profitability, AMED's ROE is +0.10%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, AMED is more volatile compared to LHCG. This indicates potentially higher risk in terms of short-term price fluctuations for AMED.
AMED vs OPCH Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, OPCH has a market cap of 5.21B. Regarding current trading prices, AMED is priced at $94.47, while OPCH trades at $31.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas OPCH's P/E ratio is 25.43. In terms of profitability, AMED's ROE is +0.10%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, AMED is less volatile compared to OPCH. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs SGRY Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, SGRY has a market cap of 3.05B. Regarding current trading prices, AMED is priced at $94.47, while SGRY trades at $23.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas SGRY's P/E ratio is -18.02. In terms of profitability, AMED's ROE is +0.10%, compared to SGRY's ROE of -0.10%. Regarding short-term risk, AMED is less volatile compared to SGRY. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs ACHC Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, ACHC has a market cap of 2.37B. Regarding current trading prices, AMED is priced at $94.47, while ACHC trades at $25.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas ACHC's P/E ratio is 12.61. In terms of profitability, AMED's ROE is +0.10%, compared to ACHC's ROE of +0.06%. Regarding short-term risk, AMED is less volatile compared to ACHC. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs LFST Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, LFST has a market cap of 2.23B. Regarding current trading prices, AMED is priced at $94.47, while LFST trades at $5.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas LFST's P/E ratio is -63.78. In terms of profitability, AMED's ROE is +0.10%, compared to LFST's ROE of -0.02%. Regarding short-term risk, AMED is less volatile compared to LFST. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs ARDT Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, ARDT has a market cap of 2.09B. Regarding current trading prices, AMED is priced at $94.47, while ARDT trades at $14.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas ARDT's P/E ratio is 8.69. In terms of profitability, AMED's ROE is +0.10%, compared to ARDT's ROE of +0.24%. Regarding short-term risk, AMED is less volatile compared to ARDT. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs ADUS Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, ADUS has a market cap of 1.99B. Regarding current trading prices, AMED is priced at $94.47, while ADUS trades at $108.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas ADUS's P/E ratio is 24.66. In terms of profitability, AMED's ROE is +0.10%, compared to ADUS's ROE of +0.08%. Regarding short-term risk, AMED is less volatile compared to ADUS. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs SEM Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, SEM has a market cap of 1.91B. Regarding current trading prices, AMED is priced at $94.47, while SEM trades at $14.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas SEM's P/E ratio is 23.98. In terms of profitability, AMED's ROE is +0.10%, compared to SEM's ROE of +0.10%. Regarding short-term risk, AMED is less volatile compared to SEM. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs AMEH Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, AMEH has a market cap of 1.83B. Regarding current trading prices, AMED is priced at $94.47, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas AMEH's P/E ratio is 39.25. In terms of profitability, AMED's ROE is +0.10%, compared to AMEH's ROE of +0.06%. Regarding short-term risk, AMED is less volatile compared to AMEH. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs NHC Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, NHC has a market cap of 1.67B. Regarding current trading prices, AMED is priced at $94.47, while NHC trades at $108.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas NHC's P/E ratio is 15.66. In terms of profitability, AMED's ROE is +0.10%, compared to NHC's ROE of +0.11%. Regarding short-term risk, AMED is less volatile compared to NHC. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs BKD Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, BKD has a market cap of 1.59B. Regarding current trading prices, AMED is priced at $94.47, while BKD trades at $6.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas BKD's P/E ratio is -6.52. In terms of profitability, AMED's ROE is +0.10%, compared to BKD's ROE of -0.96%. Regarding short-term risk, AMED is less volatile compared to BKD. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs ASTH Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, ASTH has a market cap of 1.33B. Regarding current trading prices, AMED is priced at $94.47, while ASTH trades at $26.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas ASTH's P/E ratio is 38.97. In terms of profitability, AMED's ROE is +0.10%, compared to ASTH's ROE of +0.07%. Regarding short-term risk, AMED is less volatile compared to ASTH. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs BKDT Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, BKDT has a market cap of 1.23B. Regarding current trading prices, AMED is priced at $94.47, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas BKDT's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.10%, compared to BKDT's ROE of -0.96%. Regarding short-term risk, AMED is less volatile compared to BKDT. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs MD Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, MD has a market cap of 1.22B. Regarding current trading prices, AMED is priced at $94.47, while MD trades at $14.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas MD's P/E ratio is -14.19. In terms of profitability, AMED's ROE is +0.10%, compared to MD's ROE of -0.11%. Regarding short-term risk, AMED is less volatile compared to MD. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs USPH Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, USPH has a market cap of 1.17B. Regarding current trading prices, AMED is priced at $94.47, while USPH trades at $77.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas USPH's P/E ratio is 35.42. In terms of profitability, AMED's ROE is +0.10%, compared to USPH's ROE of +0.06%. Regarding short-term risk, AMED is less volatile compared to USPH. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs AVAH Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, AVAH has a market cap of 1.14B. Regarding current trading prices, AMED is priced at $94.47, while AVAH trades at $5.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas AVAH's P/E ratio is 194.00. In terms of profitability, AMED's ROE is +0.10%, compared to AVAH's ROE of -0.12%. Regarding short-term risk, AMED is less volatile compared to AVAH. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs AGL Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, AGL has a market cap of 1.10B. Regarding current trading prices, AMED is priced at $94.47, while AGL trades at $2.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas AGL's P/E ratio is -4.75. In terms of profitability, AMED's ROE is +0.10%, compared to AGL's ROE of -0.44%. Regarding short-term risk, AMED is less volatile compared to AGL. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs HCSG Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, HCSG has a market cap of 1.04B. Regarding current trading prices, AMED is priced at $94.47, while HCSG trades at $14.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas HCSG's P/E ratio is 25.98. In terms of profitability, AMED's ROE is +0.10%, compared to HCSG's ROE of +0.08%. Regarding short-term risk, AMED is less volatile compared to HCSG. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs PNTG Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, PNTG has a market cap of 1.01B. Regarding current trading prices, AMED is priced at $94.47, while PNTG trades at $29.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas PNTG's P/E ratio is 39.08. In terms of profitability, AMED's ROE is +0.10%, compared to PNTG's ROE of +0.11%. Regarding short-term risk, AMED is less volatile compared to PNTG. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs AMN Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, AMN has a market cap of 833.26M. Regarding current trading prices, AMED is priced at $94.47, while AMN trades at $21.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas AMN's P/E ratio is -5.03. In terms of profitability, AMED's ROE is +0.10%, compared to AMN's ROE of -0.21%. Regarding short-term risk, AMED is less volatile compared to AMN. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs INNV Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, INNV has a market cap of 553.55M. Regarding current trading prices, AMED is priced at $94.47, while INNV trades at $4.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas INNV's P/E ratio is -17.08. In terms of profitability, AMED's ROE is +0.10%, compared to INNV's ROE of -0.12%. Regarding short-term risk, AMED is less volatile compared to INNV. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs CYH Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, CYH has a market cap of 550.00M. Regarding current trading prices, AMED is priced at $94.47, while CYH trades at $3.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas CYH's P/E ratio is -1.07. In terms of profitability, AMED's ROE is +0.10%, compared to CYH's ROE of +0.30%. Regarding short-term risk, AMED is less volatile compared to CYH. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs EHAB Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, EHAB has a market cap of 535.74M. Regarding current trading prices, AMED is priced at $94.47, while EHAB trades at $10.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas EHAB's P/E ratio is -3.82. In terms of profitability, AMED's ROE is +0.10%, compared to EHAB's ROE of -0.31%. Regarding short-term risk, AMED is less volatile compared to EHAB. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs TALK Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, TALK has a market cap of 517.00M. Regarding current trading prices, AMED is priced at $94.47, while TALK trades at $3.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas TALK's P/E ratio is 154.50. In terms of profitability, AMED's ROE is +0.10%, compared to TALK's ROE of -0.04%. Regarding short-term risk, AMED is less volatile compared to TALK. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs AUNA Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, AUNA has a market cap of 510.69M. Regarding current trading prices, AMED is priced at $94.47, while AUNA trades at $6.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas AUNA's P/E ratio is 15.68. In terms of profitability, AMED's ROE is +0.10%, compared to AUNA's ROE of +0.07%. Regarding short-term risk, AMED is less volatile compared to AUNA. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs SNDA Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, SNDA has a market cap of 497.29M. Regarding current trading prices, AMED is priced at $94.47, while SNDA trades at $26.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas SNDA's P/E ratio is -48.81. In terms of profitability, AMED's ROE is +0.10%, compared to SNDA's ROE of -0.53%. Regarding short-term risk, AMED is less volatile compared to SNDA. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs CCRN Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, CCRN has a market cap of 458.64M. Regarding current trading prices, AMED is priced at $94.47, while CCRN trades at $13.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas CCRN's P/E ratio is -25.91. In terms of profitability, AMED's ROE is +0.10%, compared to CCRN's ROE of -0.04%. Regarding short-term risk, AMED is less volatile compared to CCRN. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs TALKW Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, TALKW has a market cap of 435.14M. Regarding current trading prices, AMED is priced at $94.47, while TALKW trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas TALKW's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.10%, compared to TALKW's ROE of -0.04%. Regarding short-term risk, AMED is less volatile compared to TALKW. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs CMPS Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, CMPS has a market cap of 358.39M. Regarding current trading prices, AMED is priced at $94.47, while CMPS trades at $3.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas CMPS's P/E ratio is -1.94. In terms of profitability, AMED's ROE is +0.10%, compared to CMPS's ROE of -0.72%. Regarding short-term risk, AMED is less volatile compared to CMPS. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs CSU Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, CSU has a market cap of 223.71M. Regarding current trading prices, AMED is priced at $94.47, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas CSU's P/E ratio is 0.67. In terms of profitability, AMED's ROE is +0.10%, compared to CSU's ROE of +2.23%. Regarding short-term risk, AMED is less volatile compared to CSU. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs TOI Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, TOI has a market cap of 211.39M. Regarding current trading prices, AMED is priced at $94.47, while TOI trades at $2.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas TOI's P/E ratio is -3.34. In terms of profitability, AMED's ROE is +0.10%, compared to TOI's ROE of -2.73%. Regarding short-term risk, AMED is less volatile compared to TOI. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs AIRS Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, AIRS has a market cap of 199.26M. Regarding current trading prices, AMED is priced at $94.47, while AIRS trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas AIRS's P/E ratio is -11.69. In terms of profitability, AMED's ROE is +0.10%, compared to AIRS's ROE of -0.21%. Regarding short-term risk, AMED is less volatile compared to AIRS. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs AONC Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, AONC has a market cap of 175.50M. Regarding current trading prices, AMED is priced at $94.47, while AONC trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas AONC's P/E ratio is -6.74. In terms of profitability, AMED's ROE is +0.10%, compared to AONC's ROE of +0.25%. Regarding short-term risk, AMED is more volatile compared to AONC. This indicates potentially higher risk in terms of short-term price fluctuations for AMED.
AMED vs JYNT Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, JYNT has a market cap of 152.72M. Regarding current trading prices, AMED is priced at $94.47, while JYNT trades at $9.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas JYNT's P/E ratio is -52.53. In terms of profitability, AMED's ROE is +0.10%, compared to JYNT's ROE of -0.43%. Regarding short-term risk, AMED is less volatile compared to JYNT. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs BTMD Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, BTMD has a market cap of 150.88M. Regarding current trading prices, AMED is priced at $94.47, while BTMD trades at $3.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas BTMD's P/E ratio is 6.91. In terms of profitability, AMED's ROE is +0.10%, compared to BTMD's ROE of -0.19%. Regarding short-term risk, AMED is less volatile compared to BTMD. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs DCGO Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, DCGO has a market cap of 138.75M. Regarding current trading prices, AMED is priced at $94.47, while DCGO trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas DCGO's P/E ratio is -140.00. In terms of profitability, AMED's ROE is +0.10%, compared to DCGO's ROE of -0.00%. Regarding short-term risk, AMED is less volatile compared to DCGO. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs FVE Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, FVE has a market cap of 98.39M. Regarding current trading prices, AMED is priced at $94.47, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas FVE's P/E ratio is -5.64. In terms of profitability, AMED's ROE is +0.10%, compared to FVE's ROE of -0.15%. Regarding short-term risk, AMED is less volatile compared to FVE. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs PIII Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, PIII has a market cap of 58.75M. Regarding current trading prices, AMED is priced at $94.47, while PIII trades at $8.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas PIII's P/E ratio is -0.15. In terms of profitability, AMED's ROE is +0.10%, compared to PIII's ROE of -1.07%. Regarding short-term risk, AMED is less volatile compared to PIII. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs PIIIW Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, PIIIW has a market cap of 45.64M. Regarding current trading prices, AMED is priced at $94.47, while PIIIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas PIIIW's P/E ratio is -0.01. In terms of profitability, AMED's ROE is +0.10%, compared to PIIIW's ROE of -1.07%. Regarding short-term risk, AMED is less volatile compared to PIIIW. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs ALR Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, ALR has a market cap of 44.18M. Regarding current trading prices, AMED is priced at $94.47, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas ALR's P/E ratio is -1.11. In terms of profitability, AMED's ROE is +0.10%, compared to ALR's ROE of -0.15%. Regarding short-term risk, AMED is less volatile compared to ALR. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs CCEL Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, CCEL has a market cap of 40.25M. Regarding current trading prices, AMED is priced at $94.47, while CCEL trades at $4.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas CCEL's P/E ratio is 498.00. In terms of profitability, AMED's ROE is +0.10%, compared to CCEL's ROE of -0.01%. Regarding short-term risk, AMED is less volatile compared to CCEL. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs IMAC Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, IMAC has a market cap of 33.08M. Regarding current trading prices, AMED is priced at $94.47, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas IMAC's P/E ratio is -2.27. In terms of profitability, AMED's ROE is +0.10%, compared to IMAC's ROE of +2.46%. Regarding short-term risk, AMED is less volatile compared to IMAC. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs AMS Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, AMS has a market cap of 19.22M. Regarding current trading prices, AMED is priced at $94.47, while AMS trades at $2.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas AMS's P/E ratio is 9.03. In terms of profitability, AMED's ROE is +0.10%, compared to AMS's ROE of +0.09%. Regarding short-term risk, AMED is less volatile compared to AMS. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs AIH Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, AIH has a market cap of 15.93M. Regarding current trading prices, AMED is priced at $94.47, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas AIH's P/E ratio is -2.78. In terms of profitability, AMED's ROE is +0.10%, compared to AIH's ROE of -0.79%. Regarding short-term risk, AMED is less volatile compared to AIH. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs MODV Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, MODV has a market cap of 14.07M. Regarding current trading prices, AMED is priced at $94.47, while MODV trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas MODV's P/E ratio is -0.06. In terms of profitability, AMED's ROE is +0.10%, compared to MODV's ROE of +6.87%. Regarding short-term risk, AMED is less volatile compared to MODV. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs CANO Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, CANO has a market cap of 12.43M. Regarding current trading prices, AMED is priced at $94.47, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas CANO's P/E ratio is -0.01. In terms of profitability, AMED's ROE is +0.10%, compared to CANO's ROE of -32.61%. Regarding short-term risk, AMED is less volatile compared to CANO. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs KDLYW Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, KDLYW has a market cap of 11.14M. Regarding current trading prices, AMED is priced at $94.47, while KDLYW trades at $1.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas KDLYW's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.10%, compared to KDLYW's ROE of -1.46%. Regarding short-term risk, AMED is less volatile compared to KDLYW. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs FTRP Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, FTRP has a market cap of 9.81M. Regarding current trading prices, AMED is priced at $94.47, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas FTRP's P/E ratio is -1.22. In terms of profitability, AMED's ROE is +0.10%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, AMED is less volatile compared to FTRP. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs MNDR Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, MNDR has a market cap of 6.00M. Regarding current trading prices, AMED is priced at $94.47, while MNDR trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas MNDR's P/E ratio is -0.31. In terms of profitability, AMED's ROE is +0.10%, compared to MNDR's ROE of -5.70%. Regarding short-term risk, AMED is less volatile compared to MNDR. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs GBNH Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, GBNH has a market cap of 5.52M. Regarding current trading prices, AMED is priced at $94.47, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas GBNH's P/E ratio is -0.06. In terms of profitability, AMED's ROE is +0.10%, compared to GBNH's ROE of +0.51%. Regarding short-term risk, AMED is less volatile compared to GBNH. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs TOIIW Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, TOIIW has a market cap of 5.23M. Regarding current trading prices, AMED is priced at $94.47, while TOIIW trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas TOIIW's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.10%, compared to TOIIW's ROE of -2.73%. Regarding short-term risk, AMED is less volatile compared to TOIIW. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs RHE Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, RHE has a market cap of 5.21M. Regarding current trading prices, AMED is priced at $94.47, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas RHE's P/E ratio is -1.79. In terms of profitability, AMED's ROE is +0.10%, compared to RHE's ROE of +2.66%. Regarding short-term risk, AMED is less volatile compared to RHE. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs ATIP Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, ATIP has a market cap of 3.66M. Regarding current trading prices, AMED is priced at $94.47, while ATIP trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas ATIP's P/E ratio is -0.04. In terms of profitability, AMED's ROE is +0.10%, compared to ATIP's ROE of +1.77%. Regarding short-term risk, AMED is less volatile compared to ATIP. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs IMACW Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, IMACW has a market cap of 1.74M. Regarding current trading prices, AMED is priced at $94.47, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas IMACW's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.10%, compared to IMACW's ROE of +2.46%. Regarding short-term risk, AMED is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs CCM Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, CCM has a market cap of 1.19M. Regarding current trading prices, AMED is priced at $94.47, while CCM trades at $8.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas CCM's P/E ratio is -0.84. In terms of profitability, AMED's ROE is +0.10%, compared to CCM's ROE of +0.13%. Regarding short-term risk, AMED is less volatile compared to CCM. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs SYRA Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, SYRA has a market cap of 962530.00. Regarding current trading prices, AMED is priced at $94.47, while SYRA trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas SYRA's P/E ratio is -0.16. In terms of profitability, AMED's ROE is +0.10%, compared to SYRA's ROE of -1.04%. Regarding short-term risk, AMED is less volatile compared to SYRA. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs RHE-PA Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, RHE-PA has a market cap of 674535.00. Regarding current trading prices, AMED is priced at $94.47, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, AMED's ROE is +0.10%, compared to RHE-PA's ROE of +2.66%. Regarding short-term risk, AMED is less volatile compared to RHE-PA. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs BACK Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, BACK has a market cap of 119605.00. Regarding current trading prices, AMED is priced at $94.47, while BACK trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas BACK's P/E ratio is -0.01. In terms of profitability, AMED's ROE is +0.10%, compared to BACK's ROE of +2.46%. Regarding short-term risk, AMED is more volatile compared to BACK. This indicates potentially higher risk in terms of short-term price fluctuations for AMED.
AMED vs NVOS Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, NVOS has a market cap of 39460.00. Regarding current trading prices, AMED is priced at $94.47, while NVOS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas NVOS's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.10%, compared to NVOS's ROE of -1.20%. Regarding short-term risk, AMED is less volatile compared to NVOS. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs NIVFW Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, NIVFW has a market cap of 1579.00. Regarding current trading prices, AMED is priced at $94.47, while NIVFW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas NIVFW's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.10%, compared to NIVFW's ROE of -0.39%. Regarding short-term risk, AMED is less volatile compared to NIVFW. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.
AMED vs IONM Comparison
AMED plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMED stands at 3.10B. In comparison, IONM has a market cap of 313.00. Regarding current trading prices, AMED is priced at $94.47, while IONM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMED currently has a P/E ratio of 34.86, whereas IONM's P/E ratio is N/A. In terms of profitability, AMED's ROE is +0.10%, compared to IONM's ROE of +0.75%. Regarding short-term risk, AMED is less volatile compared to IONM. This indicates potentially lower risk in terms of short-term price fluctuations for AMED.